Skip to main content

China's Drug Pipeline: 14 Biotechs, 300+ Clinical Candidates

300+ Clinical Programs Across 4 Modalities

China biopharmaceutical sector has evolved from generics to a global innovation hub. A comprehensive analysis of 14 leading biotechs reveals over 300 active clinical-stage programs spanning four major drug modalities.

By the Numbers

  • Monoclonal Antibodies - BeiGene, Hengrui, and Innovent lead with 20+ mAb candidates each
  • Bispecific Antibodies - Fastest-growing category, targeting oncology and autoimmune diseases
  • Small Molecules - Including next-gen kinase inhibitors and molecular glues
  • Weight Loss Drugs - GLP-1 receptor agonists and dual/triple agonists in late-stage trials

The pipeline reflects China shift from fast-follower to first-in-class innovator, with increasing global trial participation and FDA/EMA submissions.

Get the full company-by-company pipeline breakdown with clinical trial details?

Read the complete analysis on China Industry Insights

Labels:

Comments

Post a Comment

Popular posts from this blog

China EV Sales Surge 45% in Q2 2026 as Export Markets Expand

China's electric vehicle sales surged 45% year-on-year in the second quarter of 2026, driven by strong export demand and domestic policy support, according to new industry data released Friday. Total EV deliveries reached 3.2 million units in Q2, with BYD maintaining its market leadership at 42% share. Export volumes to Europe and Southeast Asia grew 78% and 112% respectively. The growth comes as China's Ministry of Industry and Information Technology extended EV purchase tax exemptions through end of 2027, providing continued momentum for the world's largest auto market.
Post a Comment
Read more

Xiong’an’s Zero-Carbon Park: A Blueprint for Green Industry

Originally published at China Industry Intel . Read the complete report. Xiong'an's Zero-Carbon Park: A Scalable Blueprint for China's Industrial Decarbonization China’s Xiong’an New Area has unveiled a fully operational zero-carbon industrial park that integrates solar generation (50 GWh/year), green hydrogen storage (10 tons), and an AI-driven smart grid to achieve 100% energy self-sufficiency and 40,000 tons of annual CO₂ reduction. This state-sponsored demonstration project uses surplus solar power to produce hydrogen via electrolysis, storing it as a carbon-free buffer for industrial processes and reconversion to electricity. The smart grid algorithmically balances generation, storage, and consumption in real time, eliminating waste and ensuring uninterrupted operations. Critically, the modular design and proven technologies are intended to be replicated across China’s 2,000+ industrial parks, potentially cutting national industrial emissions by 8–12% by 2035 if sca...
Post a Comment
Read more

Nanda Optoelectronics: 111x PE on RMB 20M ArF Revenue—Valuation vs Reality

Originally published at China Industry Intel . Read the complete report. Nanda Optoelectronics: 111x PE on RMB 20M ArF Revenue – A Valuation Disconnect in China's Photoresist Race Nanda Optoelectronics (300346.SZ) trades at a staggering 111x P/E and a market cap of RMB 55.4 billion, yet its 2025 ArF photoresist revenue barely exceeded RMB 20 million. The company’s current capacity stands at just 50 tons per year, with no announced plans for a 500-ton expansion line. This stark gap between valuation and operational reality underscores a broader theme in China’s semiconductor material sector: the domestic substitution narrative has outpaced actual commercial execution. While the strategic imperative to localize advanced photoresists is real, technical barriers—customer qualification cycles of 2–3+ years, heavy reliance on Japanese raw material suppliers, and intense domestic competition—create a multi-year, high-risk path to material revenue. Investors are pricing in dominance bef...
Post a Comment
Read more